Overall, we found that the ‘A’ allele of rs2036527 was associated with lower abstinence rates during, and at the end of, treatment in participants who received active pharmacotherapy, but not in those who received placebo (see Fig.2C for statistical comparisons). Specifically, among the participants who received the active nicotine gum treatment (Study 1) those with the ‘A’ allele of rs2036527 had a similar magnitude of reduced abstinence throughout treatment which diminished during follow-up (during treatment OR=0.31 and end of treatment OR=0.51, Fig.2A); adjusting for age, sex, baseline CPD, menthol status and type of counseling sessions did not meaningfully alter this (during treatment OR=0.29 and end of treatment OR=0.48, Fig.2A). Likewise, adjusting for CYP2A6 genotype, the main nicotine-metabolizing enzyme, did not alter the odds ratio between rs2036527 and smoking abstinence (during treatment OR=0.31 and end of treatment OR=0.51). In the second study, a similar direction and magnitude of the rs2036527 effect was observed in those receiving the active bupropion treatment, which was not statistically significant (during treatment OR=0.54 and end of treatment OR=0.59, Fig.2B). Adjusting for age, sex, baseline CPD, and
